Category
ANTI-DIABETIC
ANTI-DIABETIC
Consistent
Purity
Global-Ready
Molecules
Advanced
Manufacturing
Scalable
Production
Partnership
Support
Sitagliptin Phosphate API has been developed by ASANA Pharmaceutical as part of its anti-diabetic product line. Sitagliptin Phosphate API, identified by CAS number 486460-32-6, is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus to improve glycemic control.
ASANA Pharmaceutical is dedicated to the development and manufacturing of high-purity anti-diabetic APIs such as Sitagliptin Phosphate. With a specialized focus on DPP-4 inhibitors and advanced synthesis methods, ASANA delivers reliable and compliant APIs to regulated markets across North America, Europe, and Asia. Our state-of-the-art facilities and robust quality framework ensure scalable production and consistent therapeutic performance.
ASANA Pharmaceutical collaborates globally with formulation specialists and research institutions, offering deep capabilities in diabetes-related chemistry, process refinement, and regulatory documentation to support long-term pharmaceutical partnerships.Sitagliptin Phosphate [CAS No. 486460-32-6], a key oral anti-diabetic agent, plays a central role in type 2 diabetes management by enhancing incretin hormone levels and improving glycemic control. As the global need for chronic disease therapies continues to grow, ASANA remains committed to delivering:
Sitagliptin Phosphate API are available on public databases such as Wikipedia. Wikipidia!